Sirona Dental Systems (SIRO) 10-Q 6 Feb 15 2015 Q1 Quarterly report Financial data

Document_and_Entity_Informatio

Document and Entity Information	3 Months Ended
	Dec. 31, 2014	Jan. 30, 2015
Document And Entity Information [Abstract]
Document Type	10-Q
Document period end date	31-Dec-14
Amendment flag	FALSE
Current fiscal year end date	-21
Entity central index key	1014507
Entity current reporting status	Yes
Entity filer category	Large Accelerated Filer
Entity registrant name	SIRONA DENTAL SYSTEMS, INC.
Entity voluntary filers	No
Trading Symbol	SIRO
Entity well known seasoned issuer	Yes
Entity common stock shares outstanding		57,981,318
Document Fiscal Year Focus	2015
Document Fiscal Period Focus	Q1

CONSOLIDATED_STATEMENTS_OF_INC

CONSOLIDATED STATEMENTS OF INCOME (UNAUDITED) (USD $)	3 Months Ended
In Millions, except Share data, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013
CONSOLIDATED STATEMENTS OF INCOME (UNAUDITED)
REVENUE	$293	$298.70
Cost of goods sold	-130.1	-136
GROSS PROFIT	162.9	162.7
Selling, general and administrative expense	-87.8	-88
Research and development expense	-14.8	-15.1
Net other operating income (loss)	2.5	2.5
OPERATING INCOME	62.8	62.1
Gain (loss) on foreign currency transactions	-2.2	-2.6
Gain (loss) on derivative instruments	0.4	0.6
Interest income (expense)	-0.9	-0.8
Other income (expense)	0.7	-0.5
INCOME BEFORE TAXES	60.8	58.8
Income tax benefit (expense)	-14	-13.8
NET INCOME	46.8	45
Net (income) loss attributable to noncontrolling interests	-0.8	-0.8
NET INCOME ATTRIBUTABLE TO SIRONA DENTAL SYSTEMS, INC.	$46	$44.20
INCOME PER SHARE (attributable to Sirona Dental Systems, Inc. common shareholders):
Basic	$0.83	$0.80
Diluted	$0.82	$0.79
Weighted average shares - basic	55,416,418	55,054,040
Weighted average shares - diluted	56,290,177	56,130,008

CONSOLIDATED_STATEMENT_OF_COMP

CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME (UNAUDITED) (USD $)	3 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013
CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME (UNAUDITED)
NET INCOME	$46.80	$45
OTHER COMPREHENSIVE INCOME (LOSS), NET OF TAX
Cumulative translation adjustment	-34.4	15.8
Derivative financial hedging instruments	-0.1	0.1
Unrecognized elements of pension cost	-0.6	0.1
TOTAL OTHER COMPREHENSIVE INCOME (LOSS)	-35.1	16
TOTAL COMPREHENSIVE INCOME (LOSS)	11.7	61
Comprehensive (income) loss attributable to noncontrolling interests	-0.8	-0.9
COMPREHENSIVE INCOME (LOSS) ATTRIBUTABLE TO SIRONA DENTAL SYSTEMS, INC. SHAREHOLDERS	$10.90	$60.10

CONSOLIDATED_BALANCE_SHEETS_UN

CONSOLIDATED BALANCE SHEETS (UNAUDITED) (USD $)	Dec. 31, 2014	Sep. 30, 2014
In Millions, unless otherwise specified
CURRENT ASSETS
Cash and cash equivalents	$368.10	$382.80
Restricted cash	0.8	0.8
Accounts receivable, net of allowance for doubtful accounts of $2.4 and $2.4, respectively	155.7	115.6
Inventories, net	125.9	123.4
Deferred tax assets	31.5	29.7
Prepaid expenses and other current assets	24.3	26.8
Income tax receivable	1.9	8
TOTAL CURRENT ASSETS	708.2	687.1
Property, plant and equipment, net of accumulated depreciation of $176.1 and $171.3, respectively	215.2	221
Goodwill	611.4	629.3
Intangible assets, net of accumulated amortization of $504.9 and $511.3, respectively	239.7	252.8
Other non-current assets	3.8	5.3
Deferred tax assets	15.6	15.5
TOTAL ASSETS	1,793.90	1,811
CURRENT LIABILITIES
Trade accounts payable	45.9	59.9
Short-term financial liabilities	24	1.5
Income taxes payable	4.1	6.1
Deferred tax liabilities	1.7	2.2
Accrued liabilities and deferred income	164	167.6
TOTAL CURRENT LIABILITIES	239.7	237.3
Long-term financial liabilities	55.5	78
Deferred tax liabilities	107.4	111.8
Other non-current liabilities	24	25.1
Pension related provisions	69.2	71.7
Deferred income	22.4	25.9
TOTAL LIABILITIES	518.2	549.8
SHAREHOLDERS` EQUITY
Preferred stock ($0.01 par value; 5,000,000 shares authorized; none issued and outstanding)	0	0
Common stock ($0.01 par value; 95,000,000 shares authorized; 57,915,531 shares issued; 55,489,462 shares outstanding at Dec. 31, 2014; 57,776,336 shares issued; 55,364,617 shares outstanding at Sept. 30, 2014)	0.6	0.6
Additional paid-in capital	703.4	697.9
Treasury stock, at cost 2,426,069 shares held at cost at Dec. 31, 2014; 2,411,719 shares held at cost at Sept. 30, 2014	-128	-126.8
Retained earnings	805.9	759.9
Accumulated other comprehensive income (loss)	-107.9	-72.8
TOTAL SIRONA DENTAL SYSTEMS, INC. SHAREHOLDERS` EQUITY	1,274	1,258.80
NONCONTROLLING INTERESTS	1.7	2.4
TOTAL SHAREHOLDERS` EQUITY	1,275.70	1,261.20
TOTAL LIABILITIES & SHAREHOLDERS` EQUITY	$1,793.90	$1,811

CONSOLIDATED_BALANCE_SHEETS_UN1

CONSOLIDATED BALANCE SHEETS (UNAUDITED) (Parentheticals) (USD $)	Dec. 31, 2014	Sep. 30, 2014
In Millions, except Share data, unless otherwise specified
CONSOLIDATED BALANCE SHEETS (UNAUDITED)
Allowance for doubtful accounts	$2.40	$2.40
Accumulated depreciation and amortization	176.1	171.3
Finite-Lived Intangible Assets, Accumulated amortization	$504.90	$511.30
Preferred stock par value per share	$0.01	$0.01
Preferred stock shares authorized	5,000,000	5,000,000
Preferred stock shares issued	0	0
Preferred stock shares outstanding	0	0
Common stock par value per share	$0.01	$0.01
Common stock shares authorized	95,000,000	95,000,000
Common stock shares issued	57,915,531	57,776,336
Common stock shares outstanding	55,489,462	55,364,617
Treasury stock shares	2,426,069	2,411,719

CONSOLIDATED_STATEMENTS_OF_CAS

CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) (USD $)	3 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013
OPERATING ACTIVITIES
NET INCOME	$46.80	$45
ADJUSTMENTS TO RECONCILE NET INCOME TO NET CASH PROVIDED BY (USED IN) OPERATING ACTIVITIES
Depreciation and amortization	17.9	19
(Gain) loss on derivative instruments and foreign currency transactions	1.8	2
Deferred income taxes	-4.6	-4
Share-based compensation expense	3.1	3.4
Other adjustments	0.1	0.1
TOTAL ADJUSTMENTS TO RECONCILE NET INCOME TO OPERATING CASH FLOWS	18.3	20.5
CHANGES IN ASSETS AND LIABILITIES
Accounts receivable	-44.2	-15.6
Inventories	-8.6	-11.4
Trade accounts payable	-12.2	-14.8
Other current and non-current assets	2.5	-0.9
Other current and non-current liabilities	-2.5	-12
Current income taxes	4.1	0.5
EFFECT OF CHANGES IN ASSETS AND LIABILITIES ON OPERATING CASH FLOWS	-60.9	-54.2
NET CASH PROVIDED BY (USED IN) OPERATING ACTIVITIES	4.2	11.3
INVESTING ACTIVITIES
Investment in property, plant and equipment	-12.3	-43.1
Proceeds from sale of property, plant and equipment	-0.1	0.3
Purchase of intangible assets	-0.2	-0.2
NET CASH PROVIDED BY (USED IN) INVESTING ACTIVITIES	-12.6	-43
FINANCING ACTIVITIES
Purchase of treasury stock	-1.2	-0.6
Dividend distributions to noncontrolling interest	0	-0.1
Common shares issued under share based compensation plans	2.1	2.3
Tax effect of common shares issued under share based compensation plans	-0.5	-1.5
NET CASH PROVIDED BY (USED IN) FINANCING ACTIVITIES	0.4	0.1
CHANGE IN CASH AND CASH EQUIVALENTS	-8	-31.6
Effect of exchange rate change on cash and cash equivalents	-6.7	0.8
Cash and cash equivalents at beginning of period	382.8	241.7
CASH AND CASH EQUIVALENTS AT END OF PERIOD	368.1	210.9
SUPPLEMENTAL INFORMATION
Interest paid	0.4	0.6
Interest capitalized	0.1	0.1
Income taxes paid	$10.90	$15

General

General	3 Months Ended
	Dec. 31, 2014
General [Abstract]
General	NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (condensed)
	1 GENERAL
	THE COMPANY AND ITS OPERATIONS
	Sirona Dental Systems, Inc. (“Sirona,” the “Company,” “we,” “us,” and “our” refer to Sirona Dental Systems, Inc. and its consolidated subsidiaries) is the leading global manufacturer of high-quality, technologically-advanced dental equipment, and is focused on developing, manufacturing, and marketing innovative systems and solutions for dentists around the world. We offer a broad range of products across all major segments of the dental technology market including CEREC and our other CAD/CAM systems, digital intra oral and 2D and 3D panoramic imaging systems, treatment centers, and instruments. The Company acquired Schick Technologies, Inc. (“Schick”) in 2006, in a transaction accounted for as a reverse acquisition (the “Exchange”), further expanding our global presence and product offerings and strengthening our research and development capabilities. Sirona has served equipment dealers and dentists worldwide for more than 130 years. The Company’s headquarters is located in Long Island City, New York with its primary facility located in Bensheim, Germany, as well as other support, manufacturing, assembling, and sales and service facilities located around the globe.

Basis_Of_Presentation_And_Summ

Basis Of Presentation And Summary Of Significant Accounting Policies	3 Months Ended
	Dec. 31, 2014
Basis of Presentation and Significant Accounting Policies [Abstract]
Basis of Presentation and Significant Accounting Policies [Text Block]	2 BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
	BASIS OF PRESENTATION
	The accompanying unaudited interim condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”). All amounts are reported in millions of U.S. Dollars ($), except per share amounts or as otherwise disclosed.
	SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
	Fiscal Year
	The Company’s fiscal year is October 1 to September 30.
	Principles of Consolidation
	The consolidated financial statements include, after eliminating inter-company transactions and balances, the accounts of Sirona Dental Systems, Inc. and its subsidiaries.
	Use of Estimates
	Preparation of the interim financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions related to the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities as at the reporting date and the reported amounts of revenues and expenses for the interim period. Actual results could differ from those estimates. Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted pursuant to such rules and regulations. However, the Company believes that the disclosures are adequate to make the information not misleading. The year-end consolidated financial data was derived from the audited consolidated financial statements, but does not include all disclosures required by U.S. GAAP. These condensed consolidated financial statements should be read in conjunction with the Consolidated Financial Statements and the Notes thereto included in the Company’s Annual Report on Form 10-K for the fiscal year ended September 30, 2014.
	In the opinion of management, all adjustments considered necessary to present fairly the Company’s financial position as of December 31, 2014, and the results of operations and cash flows for the three months ended December 31, 2014 and 2013, respectively, as applicable to interim periods have been made. The results of operations for the three months ended December 31, 2014 are not necessarily indicative of the operating results for the full fiscal year or future periods.
	Foreign Currency
	The functional currency for foreign operations has been determined in all cases to be the local currency. Adjustments resulting from translating foreign functional-currency assets and liabilities are recorded in shareholders’ equity as a component of accumulated other comprehensive income. Gains or losses resulting from transactions in other than the functional currency are reflected in the consolidated statements of income, except for intra-group transactions of a long-term nature, which are recorded in shareholders’ equity as a component of accumulated other comprehensive income.

Accounting_Standards_Issued

Accounting Standards Issued	3 Months Ended
	Dec. 31, 2014
Accounting standars issued [Abstract]
Accounting Standards Issued	3 ACCOUNTING STANDARDS ISSUED
	Changes to accounting principles generally accepted in the United States (“U.S. GAAP”) are established by the Financial Accounting Standards Board (“FASB”) in the form of Accounting Standards Updates (“ASUs”). The Company considers the applicability and impact of all ASUs. ASUs not listed below were assessed and determined to be either (i) not applicable, (ii) are expected to have a minimal impact on our consolidated financial statements, or (iii) their adoption had an immaterial impact on our consolidated financial statements.
	ADOPTED
	There were no ASUs adopted during the current period, which had a material impact on our consolidated financial statements.
	NOT YET ADOPTED
	In May 2014, the FASB issued ASU 2014-09, Revenue from Contracts with Customers, which provides updated guidance on revenue recognition principles that will supersede most current conceptual and industry-specific revenue recognition guidance and thus enhance comparability of revenue recognition practices across entities, industries, jurisdictions, and capital markets. The key principle of this updated guidance is that entities should recognize revenue to depict the transfer of goods or services to customers at an amount reflecting the consideration expected in exchange for those goods or services. The new guidance prescribes a five-step analysis of transactions to determine how and when to recognize revenue. In addition, the new guidance provides for capitalization of certain costs of obtaining or fulfilling a contract with a customer as well as enhanced disclosure requirements to enable a better understanding of the nature, amount, timing, and uncertainty of revenue and cash flows arising from contracts with customers. ASU 2014-09 is effective for public entities for fiscal years, and interim periods within those years, beginning after December 15, 2016, which corresponds to the Company’s fiscal year beginning October 1, 2017, with early adoption not permitted. The new guidance permits the use of either a retrospective or cumulative effect transition method. We have not yet selected a transition method and are evaluating the expected impact of adoption on our consolidated financial statements.

Employee_ShareBased_Compensati

Employee Share-Based Compensation	3 Months Ended
	Dec. 31, 2014
Employee Share-Based Compensation [Abstract]
Employee Share-Based Compensation	4 EMPLOYEE SHARE-BASED COMPENSATION
	ASC 718, Compensation – Stock Compensation, requires that all share based compensation arrangements, including grants of stock option awards to employees, be recognized based on the estimated fair value of the share-based payment award.
	EQUITY INCENTIVE PLAN
	Stock options, restricted stock shares, restricted stock units (“RSU”), and performance-based stock units (“PSU”) have been issued to employees, directors, and consultants under the Company’s 2006 Equity Incentive Plan (“2006 Plan”). The 2006 Plan provides for granting in total up to 4,550,000 stock options, incentive stock, restricted stock shares, RSU’s, and PSU’s. The 2006 Plan received stockholder approval at the Company’s Annual Meeting of Stockholders held on February 27, 2007, and was amended on February 25, 2009. To cover the exercise of options and vesting of RSU’s and PSU’s, the Company generally issues new shares from its authorized but unissued share pool. As of December 31, 2014, 190,656 shares were available for future grant under the 2006 Plan.
	Restricted and Performance-Based Stock Units
	In the three months ended December 31, 2014, the Company granted 118,544 RSU’s and 37,004 PSU’s with an average value of $86.00, representing the average of closing prices of the Company’s common stock at the grant dates.
	RSU’s and PSU’s generally vest in annual tranches over a period of three to five years. The PSU’s were granted to certain Company executives and vest three years from the date of the grant provided the Company achieves performance targets specified in the grant. RSU’s and PSU’s do not have voting rights or rights to dividends prior to vesting. The value of each RSU and PSU grant is determined by the closing price at the date of grant. Share-based compensation expense for the entire award is recognized straight-line over the service period of the last separately vesting tranche of the award.
	Stock Options
	In the three months ended December 31, 2014, the Company granted 160,262 stock options with a weighted average exercise price of $ 86.00 and weighted average fair value of $22.90 at the grant date. Grants generally vest over a period of four to five years. All grants expire ten years after the date of the grant.
	The fair value of options granted under the 2006 Plan was estimated using the Black-Scholes option pricing model using assumptions in the following table. The exercise price is equal to the fair market value of Sirona’s stock at the grant date. Expected volatility is based on the Company’s historical stock price volatility. The risk-free rate is based on the U.S. Treasury yield curve in effect at the day of grant and has a term equal to the expected life of the option. The expected life represents the period of time the options are expected to be outstanding based on anticipated grantee behavior. The expected dividend yield is based on the Company’s history of not paying regular dividends in the past and the Company’s current intention not to pay dividends in the foreseeable future.
		Black-Scholes Assumptions		Three months ended		Year ended
				December 31,		September 30,
				2014		2014
		Expected Volatility		26.77%		33.27%
		Risk-free rate		1.58%		1.35%
		Expected term		5 years		5 years
		Expected dividends		-		-
	COMPENSATION COSTS
	The following table summarizes compensation expense charged to income for stock-based compensation and additional information for the three months ended December 31, 2014:
		Compensation Expense		Three months ended
				December 31,
		(In millions)		2014		2013
		Compensation expense (1)	$	3.1	$	3.4
		(1) For the three months ended December 31, 2014 and 2013, this included a compensation charge of $0.2 million and $0.7 million, respectively, for share-based awards in connection with the CFO Transition.
	RESTRICTED AND PERFORMANCE-BASED STOCK UNIT ACTIVITY
	The following is a summary of Sirona’s RSU and PSU activity for the three months ended December 31, 2014:
		RSU and PSU Activity		Three months ended
				December 31,
				2014
				Restricted stock units			Performance-based stock units
				Number of shares		Weighted average market price at grant	Number of shares		Weighted average market price at grant
		Outstanding at beginning of period		491,781	$	55.81	42,566	$	66.63
		Granted		118,544		86	37,004		86
		Vested		-65,288		43.61	-		-
		Forfeited		-4,387		61.32	-		-
		Outstanding at end of period		540,650	$	61.29	79,570	$	74.91
	STOCK OPTION ACTIVITY
	The following is a summary of Sirona’s stock option activity for the three months ended December 31, 2014:
		Stock Option Activity		Three months ended
				December 31,
				2014
				Number of options		Weighted average exercise price
		Outstanding at beginning of period		1,560,592	$	29.13
		Granted		160,262		86
		Exercised		-92,384		22.43
		Expired		-1,500		27.72
		Forfeited		-600		67.59
		Outstanding at end of period		1,626,370	$	34.06
		thereof vested and exercisable		1,156,210

Net_Other_Operating_Income_Los

Net Other Operating Income (Loss)	3 Months Ended
	Dec. 31, 2014
Net Other Operating Income (Loss)[Abstract]
Net Other Operating Income	5 NET OTHER OPERATING INCOME (LOSS)
	The components of net other operating income (loss) for the periods under report are as follows:
		Net Other Operating Income (Loss)		Three months ended
				December 31,
		(In millions)		2014		2013
		Income resulting from the amortization of the deferred income related to the Patterson exclusivity payment	$	2.5	$	2.5
	DEFERRED INCOME
	Effects of remeasurement of the Patterson Exclusivity Payment from U.S. Dollar to Euro are reflected in the statement of income. For the periods under report, these effects were as follows:
		Deferred Income (Patterson Exclusivity Payment)		Three months ended
				December 31,
		(In millions)		2014		2013
		Foreign currency transaction gain (loss) resulting from the remeasurement of the deferred income related to the Patterson exclusivity payment	$	-1	$	0.8

Derivative_Instruments_and_Hed

Derivative Instruments and Hedging Strategies	3 Months Ended
	Dec. 31, 2014
Derivative Instruments And Hedging Strategies [Abstract]
Derivative Instruments and Hedging Strategies	6 DERIVATIVE INSTRUMENTS AND HEDGING STRATEGIES
	RISKS AND EXPOSURE
	Our operations are exposed to market risks from changes in foreign currency exchange rates and interest rates. In the normal course of business, these risks are managed through a variety of strategies, including the use of derivatives.
	Interest Rate Risk
	The Company is exposed to interest rate risk associated with fluctuations in the interest rates on its variable interest rate debt. In order to manage this risk, the Company enters into interest rate swap agreements, when appropriate, based upon market conditions.
	Foreign Currency Exposure
	Although the U.S. Dollar is Sirona’s reporting currency, it conducts its business in many currencies, and its local functional currency varies depending on the country of operation, which exposes the Company to market risk associated with foreign currency exchange rate movements. The Company hedges certain foreign currency transaction exposure through foreign exchange forward contracts.
	CASH FLOW HEDGES
	Interest Rate
	The Company uses interest rate swaps to convert a portion of its debt's variable interest rate to a fixed interest rate. Interest rate swaps have been established for 100% of the interest for the Facility A Term Loan under the Senior Facilities Agreement until November 2016. The interest rate swaps fix the LIBOR element of interest payable on 100% of the principal amount of the Facility A Term Loan for defined three month interest periods over the entire term of the loan. The defined interest rates fixed for each three month interest period range from 1.270% to 1.285%. Settlement of the swaps is required on a quarterly basis. These swaps are designated as hedging instruments under ASC 815. These instruments were immaterial for all periods under report. The Company enters into interest rate swap contracts infrequently as they are only used to manage interest rate risk on long-term debt instruments.
	Foreign Currency
	The Euro is the functional currency for many of Sirona’s subsidiaries, including its primary sales and manufacturing operations in Germany. During the periods under review, the U.S. Dollar/Euro exchange rate fluctuated significantly, thereby impacting Sirona’s financial results. In order to hedge portions of the transactional exposure to fluctuations in exchange rates, based on forecasted and firmly-committed cash flows, Sirona enters into foreign exchange forward contracts (currently: USD, AUD, and JPY). These forward foreign currency contracts are intended to reduce short-term effects of changes in exchange rates. The Company enters into forward contracts that are considered to be economic hedges but which are not considered hedging instruments under ASC 815. As of December 31, 2014, these contracts had notional amounts totaling $46.4 million. These agreements are relatively short-term (generally not exceeding six months).
	The fair value carrying amount of the Company's derivative instruments at December 31, 2014 is described in Note 13 Fair Value Measurements.
	The following tables summarize the impact of gains and losses from the fair value changes of the Company’s derivative instruments reported in our condensed consolidated statements of income for the periods under report:
		Derivatives Not Designated as Hedging Instruments
		Amount of Gain (Loss) Recognized in Income on Derivative Instruments		Three months ended
				December 31,
		(In millions)		2014		2013	Affected Line Item in the Statement of Income
		Foreign exchange contracts	$	0.4	$	0.6	Gain (loss) on derivative instruments, net

Income_Taxes

Income Taxes	3 Months Ended
	Dec. 31, 2014
Income Taxes [Abstract]
Income Taxes	7 INCOME TAXES
	For the first three months of fiscal year 2015, an estimated effective tax rate of 23.0 % has been applied (prior year period: 23.5 %). The income tax provision for the first three months ended December 31, 2014, was $ 14.0 million (prior year period: $ 13.8 million). The actual effective tax rate for fiscal year 2014 was 23.0 %.
	The Company's effective tax rate may vary significantly from period to period, and can be influenced by many factors. These factors include, but are not limited to, changes to statutory tax rates in the jurisdictions where the Company has operations, changes in the mix of earnings amongst jurisdictions with differing statutory tax rates (including as a result of business acquisitions and dispositions), changes in the valuation of deferred tax assets and liabilities, the results of audits and examinations of previously filed tax returns, tax planning initiatives, tax characteristics of income, as well as the timing and deductibility of expenses for tax purposes. The Company's effective tax rate differs from the U.S. federal statutory rate of 35% primarily as a result of lower statutory tax rates on foreign earnings at the Company’s operations outside of the United States. The distribution of lower-taxed foreign earnings to the U.S. would generally increase the Company's effective tax rate.
	With limited exception, the Company and its subsidiaries are no longer subject to U.S. federal, state and local or non-U.S. income tax examinations by taxing authorities for tax returns filed with respect to periods prior to fiscal year 2009.
	The Company makes no provision for deferred U.S. income taxes on undistributed foreign earnings because as of December 31, 2014, it remained management’s intention to continue to indefinitely reinvest such earnings in foreign operations. In making this determination, the Company also evaluates its expected cash requirements in the United States. These earnings relate to ongoing operations and, as of December 31, 2014, the approximate amount of undistributed foreign earnings amounted to $587 million. Because of the availability of U.S. foreign tax credits as well as other factors, it is not practicable to determine the income tax liability that would be payable if such earnings were not reinvested indefinitely.

Income_per_Share

Income per Share	3 Months Ended
	Dec. 31, 2014
Income per Share [Abstract]
Income per Share	8 INCOME PER SHARE
	The computation of basic and diluted income per share is as follows:
		Income per Share		Three months ended
				December 31,
		(In millions, except share and per share amounts)		2014		2013
		Net income attributable to Sirona Dental Systems, Inc. common shareholders	$	46	$	44.2
		Weighted average shares outstanding - basic		55,416,418		55,054,040
		Dilutive effect of stock-based compensation (1)		873,759		1,075,968
		Weighted average shares outstanding - diluted		56,290,177		56,130,008
		Net income per share
		Basic	$	0.83	$	0.8
		Diluted	$	0.82	$	0.79
		(1) There were no stock options excluded from the computation of diluted earnings per share for the periods under report.

Segment_Reporting

Segment Reporting	3 Months Ended
	Dec. 31, 2014
Segment Reporting [Abstract]
Segment reporting	9 SEGMENT REPORTING
	SEGMENT RESULTS
	The following tables reflect the results of the Company’s reportable segments under the Company’s management reporting system. The segment performance measure used to monitor segment performance is gross profit (‘‘Segment Performance Measure’’) excluding the impact of the acquisition of control of the Sirona business by Sirona Holdings Luxco S.C.A. (“Luxco”) – the former controlling shareholder, a Luxembourg-based holding entity owned by funds managed by Madison Dearborn Partners (“MDP”); Beecken Petty O’Keefe and management of Sirona through a leveraged buyout transaction on June 30, 2005 (the “MDP Transaction”); and the Exchange. This measure is considered by management to better reflect the performance of each segment as it eliminates the need to allocate centrally incurred costs and significant purchase accounting impacts that the Company does not believe are representative of the performance of the segments. Furthermore, the Company monitors performance geographically by region. As the Company manages its business on both a product and a geographical basis, U.S. GAAP requires segmental disclosure based on product information.
		Segment Performance		Three months ended
				December 31,
		(In millions)		2014		2013
		Revenue External
		Dental CAD/CAM Systems	$	98.2	$	105.8
		Imaging Systems		108		105.8
		Treatment Centers		54		54.4
		Instruments		32.8		32.7
		Total	$	293	$	298.7
		Segment performance measure (gross profit)
		Dental CAD/CAM Systems	$	68.4	$	73.3
		Imaging Systems		63.4		61.5
		Treatment Centers		21.5		21.2
		Instruments		13.4		13.5
		Total Segments	$	166.7	$	169.5
	RECONCILIATION OF THE RESULTS OF THE SEGMENT PERFORMANCE MEASURE TO THE CONSOLIDATED STATEMENTS OF INCOME
	The following table provides a reconciliation of the total results of operations of the Company’s business segments under management reporting to the consolidated financial statements. The differences shown between management reporting and U.S. GAAP for the three months ended December 31, 2014 and 2013 are due to the impact of purchase accounting and certain other corporate items. These effects are not included in the segment performance measure as the Company does not believe these to be representative of the performance of each segment.
		Reconciliation of Segment Performance Measure to Consolidated Statement of Income		Three months ended
				December 31,
		(In millions)		2014		2013
		Consolidated revenue	$	293	$	298.7
		Segment performance measure (gross profit)
		Total segments		166.7		169.5
		Differences management reporting vs. U.S. GAAP (including step-up depreciation and amortization and certain other corporate items)		-3.8		-6.8
		Consolidated gross profit		162.9		162.7
		Selling, general and administrative expense		-87.8		-88
		Research and development expense		-14.8		-15.1
		Net other operating income (loss)		2.5		2.5
		Gain (loss) on foreign currency transactions		-2.2		-2.6
		Gain (loss) on derivative instruments		0.4		0.6
		Interest income (expense)		-0.9		-0.8
		Other income (expense)		0.7		-0.5
		Income before taxes	$	60.8	$	58.8
	CONCENTRATION OF REVENUE
	A substantial portion of our revenue comes from two distributors accounting for more than 10% of revenues. Patterson Companies, Inc. (“Patterson”) and Henry Schein, Inc. (“Henry Schein”) accounted for revenues and accounts receivable for the three months ended December 31, 2014 compared to the three months ended December 31, 2013 as shown in the table below. These revenues were earned across all segments, with a significant portion of revenues with Patterson being earned in the CAD/CAM and Imaging segments. No other customer accounted for more than 10% of revenues.
		Concentration of Revenue		Three months ended
				December 31,
		(In millions, except for percent amounts)		2014		2013
		Top Customers
		Revenues
		Patterson Dental Company, Inc.		35%		34%
		Henry Schein, Inc.		13%		13%
		Total of customers > 10% revenues		48%		47%
		Accounts Receivable
		Patterson Dental Company, Inc.	$	69.8	$	76.1
		Henry Schein, Inc.		13.8		11.4
		Total Accounts Receivable of customers > 10% revenues	$	83.6	$	87.5

Accumulated_Other_Comprehensiv

Accumulated Other Comprehensive Income/(Loss)	3 Months Ended
	Dec. 31, 2014
Accumulated Other Comprehensive Income/(Loss) [Abstract]
Accumulated Other Comprehensive Income	10 ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS)
	The components and development of accumulated other comprehensive income (loss) for the periods under report are as follows:
		Accumulated Other Comprehensive Income (Loss)		Three months ended
				December 31,
				2014
		(In millions)		Cumulative translation adjustments		Unrecognized elements of pension cost		Net gain (loss) from hedging instruments		Total
		Balance at beginning of period	$	-85.6	$	13.2	$	-0.4	$	-72.8
		Current increase (decrease)		-34.4		-0.9		-0.1		-35.4
		Income tax (expense) benefit		-		0.3		-		0.3
		Balance at end of period		-120		12.6		-0.5		-107.9
		Balance at end of period attributable to Sirona Dental Systems, Inc. shareholders	$	-120	$	12.6	$	-0.5	$	-107.9
		Accumulated Other Comprehensive Income (Loss)		Three months ended
				December 31,
				2013
		(In millions)		Cumulative translation adjustments		Unrecognized elements of pension cost		Net gain (loss) from hedging instruments		Total
		Balance at beginning of period	$	2.9	$	6.4	$	-0.7	$	8.6
		Current increase (decrease)		15.8		0.1		0.1		16
		Balance at end of period		18.7		6.5		-0.6		24.6
		Other comprehensive income (loss) attributable to noncontrolling interests, net of tax		0.1		-		-		0.1
		Balance at end of period attributable to Sirona Dental Systems, Inc. shareholders	$	18.6	$	6.5	$	-0.6	$	24.5

Inventories_net

Inventories, net	3 Months Ended
	Dec. 31, 2014
Inventories, net [Abstract]
Inventories, net	11 INVENTORIES, NET
	The components of net inventories for the periods under report are as follows:
		Inventories		December 31,		September 30,
		(In millions)		2014		2014
		Finished goods	$	90.6	$	86.8
		Work in progress		12.3		14.3
		Raw materials		41.7		39.7
		Inventories, gross		144.6		140.8
		Inventory reserve		-18.7		-17.4
		Inventories, net	$	125.9	$	123.4

Product_Warranty

Product Warranty	3 Months Ended
	Dec. 31, 2014
Product warranty [Abstract]
Product warranty	12 PRODUCT WARRANTY
	The following table provides the components of and changes in the product warranty accrual for the periods under report:
		Product Warranty		Three months ended
				December 31,
		(In millions)		2014		2013
		Balance at beginning of the period	$	7.6	$	9.7
		Accruals for warranties issued		4.7		5.6
		Warranty settlements made		-4.8		-5.3
		Translation adjustment		-0.2		0.2
		Balance at end of the period	$	7.3	$	10.2

Fair_Value_Measurements

Fair Value Measurements	3 Months Ended
	Dec. 31, 2014
Fair Value Measurements [Abstract]
Fair Value Measurements	13 FAIR VALUE MEASUREMENTS
	The Company applies the provisions of ASC 820, Fair Value Measurements and Disclosures, for assets and liabilities that are recognized or disclosed at fair value in the financial statements on a recurring basis. ASC 820 defines fair value as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. When determining the fair value measurements for assets and liabilities that are required to be recorded or disclosed at fair value, the Company considers the principal or most advantageous market in which it would transact and the market-based risk measurements or assumptions that market participants would use in pricing the asset or liability, such as inherent risk, transfer restrictions, and the credit risk of the Company and counterparties to the arrangement.
	ASC 820 establishes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into three levels. A financial instrument’s categorization within the fair value hierarchy is based upon the lowest level of input that is available and significant to the fair value measurement. ASC 820 establishes and prioritizes the following three levels of inputs that may be used to measure fair value:
	Level 1
	Quoted prices in active markets for identical assets or liabilities.
	Level 2
	Observable inputs other than quoted prices in active markets for identical assets and liabilities, quoted prices for identical or similar assets or liabilities in inactive markets, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.
	Level 3
	Inputs that are generally unobservable and typically reflect management’s estimates of assumptions that market participants would use in pricing the asset or liability.
	FAIR VALUE OF FINANCIAL INSTRUMENTS
	Financial instruments consist of cash, cash equivalents, accounts receivable, accounts payable, foreign currency forward contracts, interest rate swaps, and certain liabilities related to business acquisitions primarily resulting from earn-out features. The carrying amounts of cash, cash equivalents, accounts receivable and accounts payable approximate their respective fair values because of the short maturity and nature of these items. The fair value of the foreign currency forward contracts and interest rate swaps is determined by the estimated cash flows of those contracts and swaps. The fair values of the acquisition-related liabilities are based on discounted valuations of commercial assumptions made by Company management of stipulations governed in the underlying purchase agreements.
	ASSETS/LIABILITIES MEASURED AT FAIR VALUE ON A RECURRING BASIS
	The following table presents the Company’s assets and liabilities measured at fair value on a recurring basis for the periods under report:
		Assets and Liabilities Measured at Fair Value - Recurring Basis		December 31,
				2014
				Quoted Pricesin ActiveMarkets forIdenticalInstruments(Level 1)		SignificantOtherObservableInputs(Level 2)		SignificantUnobservableInputs(Level 3)		Total
		(In millions)				Foreign Exchange
		Assets
		Cash Equivalents(money market funds)	$	186.4	$	-	$	-	$	186.4
		Derivative Assets		-		0.2		-		0.2
		Liabilities
		Derivative Liabilities		-		-1.3		-		-1.3
		Business Combination-related liabilities		-		-		-13.3		-13.3
		Total	$	186.4	$	-1.1	$	-13.3	$	172
		Assets and Liabilities Measured at Fair Value - Recurring Basis		September 30,
				2014
				Quoted Pricesin ActiveMarkets forIdenticalInstruments(Level 1)		SignificantOtherObservableInputs(Level 2)		SignificantUnobservableInputs(Level 3)		Total
		(In millions)				Foreign Exchange
		Assets
		Cash Equivalents(money market funds)	$	211.2	$	-	$	-	$	211.2
		Liabilities
		Derivative Liabilities		-		-1.5		-		-1.5
		Business Combination-related liabilities		-		-		-14.2		-14.2
		Total	$	211.2	$	-1.5	$	-14.2	$	195.5
	The change in the fair value of the business acquisition-related liabilities was $0.9 million for the period under report, and a total for all acquisitions of $0.7 million was recorded in other income (expense) in the income statement for the three months ended December 31, 2014.
	In the Company’s December 31, 2014 and September 30, 2014 Consolidated Balance Sheet, derivative assets and derivative liabilities are classified as prepaid expenses and other current assets and accrued liabilities and deferred income, respectively.
	The Company did not elect the fair value option for any other eligible financial instruments.

General_Policies

General (Policies)	3 Months Ended
	Dec. 31, 2014
General [Abstract]
The Company and its Operations	THE COMPANY AND ITS OPERATIONS
	Sirona Dental Systems, Inc. (“Sirona,” the “Company,” “we,” “us,” and “our” refer to Sirona Dental Systems, Inc. and its consolidated subsidiaries) is the leading global manufacturer of high-quality, technologically-advanced dental equipment, and is focused on developing, manufacturing, and marketing innovative systems and solutions for dentists around the world. We offer a broad range of products across all major segments of the dental technology market including CEREC and our other CAD/CAM systems, digital intra oral and 2D and 3D panoramic imaging systems, treatment centers, and instruments. The Company acquired Schick Technologies, Inc. (“Schick”) in 2006, in a transaction accounted for as a reverse acquisition (the “Exchange”), further expanding our global presence and product offerings and strengthening our research and development capabilities. Sirona has served equipment dealers and dentists worldwide for more than 130 years. The Company’s headquarters is located in Long Island City, New York with its primary facility located in Bensheim, Germany, as well as other support, manufacturing, assembling, and sales and service facilities located around the globe.
Basis of Presentation	BASIS OF PRESENTATION
	The accompanying unaudited interim condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”). All amounts are reported in millions of U.S. Dollars ($), except per share amounts or as otherwise disclosed.
Fiscal year	Fiscal Year
	The Company’s fiscal year is October 1 to September 30.
Principles of consolidation	Principles of Consolidation
	The consolidated financial statements include, after eliminating inter-company transactions and balances, the accounts of Sirona Dental Systems, Inc. and its subsidiaries.
Use of Estimates	Use of Estimates
	Preparation of the interim financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions related to the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities as at the reporting date and the reported amounts of revenues and expenses for the interim period. Actual results could differ from those estimates. Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted pursuant to such rules and regulations. However, the Company believes that the disclosures are adequate to make the information not misleading. The year-end consolidated financial data was derived from the audited consolidated financial statements, but does not include all disclosures required by U.S. GAAP. These condensed consolidated financial statements should be read in conjunction with the Consolidated Financial Statements and the Notes thereto included in the Company’s Annual Report on Form 10-K for the fiscal year ended September 30, 2014.
	In the opinion of management, all adjustments considered necessary to present fairly the Company’s financial position as of December 31, 2014, and the results of operations and cash flows for the three months ended December 31, 2014 and 2013, respectively, as applicable to interim periods have been made. The results of operations for the three months ended December 31, 2014 are not necessarily indicative of the operating results for the full fiscal year or future periods.
Foreign Currency	Foreign Currency
	The functional currency for foreign operations has been determined in all cases to be the local currency. Adjustments resulting from translating foreign functional-currency assets and liabilities are recorded in shareholders’ equity as a component of accumulated other comprehensive income. Gains or losses resulting from transactions in other than the functional currency are reflected in the consolidated statements of income, except for intra-group transactions of a long-term nature, which are recorded in shareholders’ equity as a component of accumulated other comprehensive income.
Derivative Instruments and Hedging Strategies	DERIVATIVE INSTRUMENTS AND HEDGING STRATEGIES
	RISKS AND EXPOSURE
	Our operations are exposed to market risks from changes in foreign currency exchange rates and interest rates. In the normal course of business, these risks are managed through a variety of strategies, including the use of derivatives.
	Interest Rate Risk
	The Company is exposed to interest rate risk associated with fluctuations in the interest rates on its variable interest rate debt. In order to manage this risk, the Company enters into interest rate swap agreements, when appropriate, based upon market conditions.
	Foreign Currency Exposure
	Although the U.S. Dollar is Sirona’s reporting currency, it conducts its business in many currencies, and its local functional currency varies depending on the country of operation, which exposes the Company to market risk associated with foreign currency exchange rate movements. The Company hedges certain foreign currency transaction exposure through foreign exchange forward contracts.
	Interest Rate
	The Company uses interest rate swaps to convert a portion of its debt's variable interest rate to a fixed interest rate.
Fair Value of Financial Instruments	FAIR VALUE OF FINANCIAL INSTRUMENTS
	Financial instruments consist of cash, cash equivalents, accounts receivable, accounts payable, foreign currency forward contracts, interest rate swaps, and certain liabilities related to business acquisitions primarily resulting from earn-out features. The carrying amounts of cash, cash equivalents, accounts receivable and accounts payable approximate their respective fair values because of the short maturity and nature of these items. The fair value of the foreign currency forward contracts and interest rate swaps is determined by the estimated cash flows of those contracts and swaps. The fair values of the acquisition-related liabilities are based on discounted valuations of commercial assumptions made by Company management of stipulations governed in the underlying purchase agreements.

Employee_ShareBased_Compensati1

Employee Share-Based Compensation (Tables)	3 Months Ended
	Dec. 31, 2014
Employee Share-Based Compensation [Abstract]
Schedule of Black-Scholes assumptions (option pricing)		Black-Scholes Assumptions		Three months ended		Year ended
				December 31,		September 30,
				2014		2014
		Expected Volatility		26.77%		33.27%
		Risk-free rate		1.58%		1.35%
		Expected term		5 years		5 years
		Expected dividends		-		-
Schedule of compensation expense and other information		Compensation Expense		Three months ended
				December 31,
		(In millions)		2014		2013
		Compensation expense (1)	$	3.1	$	3.4
		(1) For the three months ended December 31, 2014 and 2013, this included a compensation charge of $0.2 million and $0.7 million, respectively, for share-based awards in connection with the CFO Transition.
Schedule of restricted and performance-based stock unit activity		RSU and PSU Activity		Three months ended
				December 31,
				2014
				Restricted stock units			Performance-based stock units
				Number of shares		Weighted average market price at grant	Number of shares		Weighted average market price at grant
		Outstanding at beginning of period		491,781	$	55.81	42,566	$	66.63
		Granted		118,544		86	37,004		86
		Vested		-65,288		43.61	-		-
		Forfeited		-4,387		61.32	-		-
		Outstanding at end of period		540,650	$	61.29	79,570	$	74.91
Schedule of stock option activity		Stock Option Activity		Three months ended
				December 31,
				2014
				Number of options		Weighted average exercise price
		Outstanding at beginning of period		1,560,592	$	29.13
		Granted		160,262		86
		Exercised		-92,384		22.43
		Expired		-1,500		27.72
		Forfeited		-600		67.59
		Outstanding at end of period		1,626,370	$	34.06
		thereof vested and exercisable		1,156,210

Net_Other_Operating_Income_Los1

Net Other Operating Income (Loss) (Table)	3 Months Ended
	Dec. 31, 2014
Net Other Operating Income (Loss)[Abstract]
Schedule of net other operating income (loss)		Net Other Operating Income (Loss)		Three months ended
				December 31,
		(In millions)		2014		2013
		Income resulting from the amortization of the deferred income related to the Patterson exclusivity payment	$	2.5	$	2.5
Schedule of deferred income		Deferred Income (Patterson Exclusivity Payment)		Three months ended
				December 31,
		(In millions)		2014		2013
		Foreign currency transaction gain (loss) resulting from the remeasurement of the deferred income related to the Patterson exclusivity payment	$	-1	$	0.8

Derivative_Instruments_and_Hed1

Derivative Instruments and Hedging Strategies (Tables)	3 Months Ended
	Dec. 31, 2014
Derivative Instruments And Hedging Strategies [Abstract]
Schedule of derivative instruments, location and amount of gains and losses		Derivatives Not Designated as Hedging Instruments
		Amount of Gain (Loss) Recognized in Income on Derivative Instruments		Three months ended
				December 31,
		(In millions)		2014		2013	Affected Line Item in the Statement of Income
		Foreign exchange contracts	$	0.4	$	0.6	Gain (loss) on derivative instruments, net

Income_per_Share_Tables

Income per Share (Tables)	3 Months Ended
	Dec. 31, 2014
Income per Share [Abstract]
Schedule of income per share		Income per Share		Three months ended
				December 31,
		(In millions, except share and per share amounts)		2014		2013
		Net income attributable to Sirona Dental Systems, Inc. common shareholders	$	46	$	44.2
		Weighted average shares outstanding - basic		55,416,418		55,054,040
		Dilutive effect of stock-based compensation (1)		873,759		1,075,968
		Weighted average shares outstanding - diluted		56,290,177		56,130,008
		Net income per share
		Basic	$	0.83	$	0.8
		Diluted	$	0.82	$	0.79
		(1) There were no stock options excluded from the computation of diluted earnings per share for the periods under report.

Segment_reporting_Tables

Segment reporting (Tables)	3 Months Ended
	Dec. 31, 2014
Segment Reporting [Abstract]
Schedule of segment reporting information by segment		Segment Performance		Three months ended
				December 31,
		(In millions)		2014		2013
		Revenue External
		Dental CAD/CAM Systems	$	98.2	$	105.8
		Imaging Systems		108		105.8
		Treatment Centers		54		54.4
		Instruments		32.8		32.7
		Total	$	293	$	298.7
		Segment performance measure (gross profit)
		Dental CAD/CAM Systems	$	68.4	$	73.3
		Imaging Systems		63.4		61.5
		Treatment Centers		21.5		21.2
		Instruments		13.4		13.5
		Total Segments	$	166.7	$	169.5
Schedule of reconciliation of operating profit (loss) from segments to consolidated		Reconciliation of Segment Performance Measure to Consolidated Statement of Income		Three months ended
				December 31,
		(In millions)		2014		2013
		Consolidated revenue	$	293	$	298.7
		Segment performance measure (gross profit)
		Total segments		166.7		169.5
		Differences management reporting vs. U.S. GAAP (including step-up depreciation and amortization and certain other corporate items)		-3.8		-6.8
		Consolidated gross profit		162.9		162.7
		Selling, general and administrative expense		-87.8		-88
		Research and development expense		-14.8		-15.1
		Net other operating income (loss)		2.5		2.5
		Gain (loss) on foreign currency transactions		-2.2		-2.6
		Gain (loss) on derivative instruments		0.4		0.6
		Interest income (expense)		-0.9		-0.8
		Other income (expense)		0.7		-0.5
		Income before taxes	$	60.8	$	58.8
Schedule of concentration of revenue		Concentration of Revenue		Three months ended
				December 31,
		(In millions, except for percent amounts)		2014		2013
		Top Customers
		Revenues
		Patterson Dental Company, Inc.		35%		34%
		Henry Schein, Inc.		13%		13%
		Total of customers > 10% revenues		48%		47%
		Accounts Receivable
		Patterson Dental Company, Inc.	$	69.8	$	76.1
		Henry Schein, Inc.		13.8		11.4
		Total Accounts Receivable of customers > 10% revenues	$	83.6	$	87.5

Accumulated_Other_Comprehensiv1

Accumulated Other Comprehensive Income (Tables)	3 Months Ended
	Dec. 31, 2014
Accumulated Other Comprehensive Income/(Loss) [Abstract]
Schedule of Comprehensive Income (Loss)		Accumulated Other Comprehensive Income (Loss)		Three months ended
				December 31,
				2014
		(In millions)		Cumulative translation adjustments		Unrecognized elements of pension cost		Net gain (loss) from hedging instruments		Total
		Balance at beginning of period	$	-85.6	$	13.2	$	-0.4	$	-72.8
		Current increase (decrease)		-34.4		-0.9		-0.1		-35.4
		Income tax (expense) benefit		-		0.3		-		0.3
		Balance at end of period		-120		12.6		-0.5		-107.9
		Balance at end of period attributable to Sirona Dental Systems, Inc. shareholders	$	-120	$	12.6	$	-0.5	$	-107.9
		Accumulated Other Comprehensive Income (Loss)		Three months ended
				December 31,
				2013
		(In millions)		Cumulative translation adjustments		Unrecognized elements of pension cost		Net gain (loss) from hedging instruments		Total
		Balance at beginning of period	$	2.9	$	6.4	$	-0.7	$	8.6
		Current increase (decrease)		15.8		0.1		0.1		16
		Balance at end of period		18.7		6.5		-0.6		24.6
		Other comprehensive income (loss) attributable to noncontrolling interests, net of tax		0.1		-		-		0.1
		Balance at end of period attributable to Sirona Dental Systems, Inc. shareholders	$	18.6	$	6.5	$	-0.6	$	24.5

Inventories_net_Tables

Inventories, net (Tables)	3 Months Ended
	Dec. 31, 2014
Inventories, net [Abstract]
Schedule of inventories, net		Inventories		December 31,		September 30,
		(In millions)		2014		2014
		Finished goods	$	90.6	$	86.8
		Work in progress		12.3		14.3
		Raw materials		41.7		39.7
		Inventories, gross		144.6		140.8
		Inventory reserve		-18.7		-17.4
		Inventories, net	$	125.9	$	123.4

Product_warranty_Tables

Product warranty (Tables)	3 Months Ended
	Dec. 31, 2014
Product warranty [Abstract]
Schedule of product warranty		Product Warranty		Three months ended
				December 31,
		(In millions)		2014		2013
		Balance at beginning of the period	$	7.6	$	9.7
		Accruals for warranties issued		4.7		5.6
		Warranty settlements made		-4.8		-5.3
		Translation adjustment		-0.2		0.2
		Balance at end of the period	$	7.3	$	10.2

Fair_Value_Measurements_Tables

Fair Value Measurements (Tables)	3 Months Ended
	Dec. 31, 2014
Fair Value Measurements [Abstract]
Schedule of fair value by Balance Sheet grouping		Assets and Liabilities Measured at Fair Value - Recurring Basis		December 31,
				2014
				Quoted Pricesin ActiveMarkets forIdenticalInstruments(Level 1)		SignificantOtherObservableInputs(Level 2)		SignificantUnobservableInputs(Level 3)		Total
		(In millions)				Foreign Exchange
		Assets
		Cash Equivalents(money market funds)	$	186.4	$	-	$	-	$	186.4
		Derivative Assets		-		0.2		-		0.2
		Liabilities
		Derivative Liabilities		-		-1.3		-		-1.3
		Business Combination-related liabilities		-		-		-13.3		-13.3
		Total	$	186.4	$	-1.1	$	-13.3	$	172
		Assets and Liabilities Measured at Fair Value - Recurring Basis		September 30,
				2014
				Quoted Pricesin ActiveMarkets forIdenticalInstruments(Level 1)		SignificantOtherObservableInputs(Level 2)		SignificantUnobservableInputs(Level 3)		Total
		(In millions)				Foreign Exchange
		Assets
		Cash Equivalents(money market funds)	$	211.2	$	-	$	-	$	211.2
		Liabilities
		Derivative Liabilities		-		-1.5		-		-1.5
		Business Combination-related liabilities		-		-		-14.2		-14.2
		Total	$	211.2	$	-1.5	$	-14.2	$	195.5

Employee_ShareBased_Compensati2

Employee Share-Based Compensation (Details) (USD $)	3 Months Ended	12 Months Ended
	Dec. 31, 2014	Sep. 30, 2014
Equity incentive plan
Share-based compensation, options granted in period	160,262
Share-based compensation, grants in period weighted average exercised price	86
Share-based compensation, weighted average grant date fair value	22.9
Stock Options
Equity incentive plan
Share-based compensation, options expiration date	10 years
Stock Options | Minimum
Equity incentive plan
Share-based compensation, award vesting period	4 years
Stock Options | Maximum
Equity incentive plan
Share-based compensation, award vesting period	5 years
2006 Plan
Equity incentive plan
Share-based compensation, total number of stock options authorized	4,550,000
Share-based compensation, number of shares available for future grant	190,656
2006 Plan | RSU
Equity incentive plan
Granted, weighted average market price at grant	86
Granted, number of shares	118,544
2006 Plan | RSU | Minimum
Equity incentive plan
Share-based compensation, award vesting period	3 years
2006 Plan | RSU | Maximum
Equity incentive plan
Share-based compensation, award vesting period	5 years
2006 Plan | PSU
Equity incentive plan
Share-based compensation, award vesting period	3 years
Granted, weighted average market price at grant	86
Granted, number of shares	37,004
2006 Plan | Stock Options
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology [Abstract]
Expected Volatility	26.77%	33.27%
Risk-free rate	1.58%	1.35%
Expected term	5 years	5 years
Expected dividends	0.00%	0.00%

Employee_ShareBased_Compensati3

Employee Share-Based Compensation (Details 1) (USD $)	3 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Compensation Expense	$3.10	$3.40
Compensation charge in connection with CFO and CEO and Chairman Transition	$0.20	$0.70

Employee_ShareBased_Compensati4

Employee Share-Based Compensation (Details 2) (USD $)	3 Months Ended
	Dec. 31, 2014
RSU
Restricted and Performance-Based Stock Unit Activity
Outstanding at beginning of period, number of shares	491,781
Granted, number of shares	118,544
Vested, number of shares	-65,288
Forfeited, number of shares	-4,387
Outstanding at end of period, number of shares	540,650
Outstanding at beginning of period, weighted average market price at grant	$55.81
Granted, weighted average market price at grant	$86
Vested, weighted average market price at grant	$43.61
Forfeited, weighted average market price at grant	$61.32
Outstanding at end of period, weighted average market price at grant	$61.29
PSU
Restricted and Performance-Based Stock Unit Activity
Outstanding at beginning of period, number of shares	42,566
Granted, number of shares	37,004
Vested, number of shares	0
Forfeited, number of shares	0
Outstanding at end of period, number of shares	79,570
Outstanding at beginning of period, weighted average market price at grant	$66.63
Granted, weighted average market price at grant	$86
Vested, weighted average market price at grant	$0
Forfeited, weighted average market price at grant	$0
Outstanding at end of period, weighted average market price at grant	$74.91

Employee_ShareBased_Compensati5

Employee Share-Based Compensation (Details 3) (USD $)	3 Months Ended
	Dec. 31, 2014
Stock option activity
Outstanding at beginning of period, number of options	1,560,592
Granted, number of options	160,262
Exercised, number of options	-92,384
Expired, number of options	-1,500
Forfeited, number of options	-600
Outstanding at end of period, number of options	1,626,370
thereof vested and exercisable	1,156,210
Stock option activity, weighted average exercise price
Outstanding at beginning of period, weighted average exercise price	$29.13
Granted, weighted average exercise price	$86
Exercised, weighted average exercise price	$22.43
Expired, weighted average exercise price	$27.72
Forfeited, weighted average exercise price	$67.59
Outstanding at end of period, weighted average exercise price	$34.06

Net_Other_Operating_Income_Los2

Net Other Operating Income (Loss)(Details) (USD $)	3 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013
Net Other Operating Income (Loss)[Abstract]
Income resulting from the amortization of the deferred income related to the Patterson exclusivity payment	$2.50	$2.50

Net_Other_Operating_Income_Los3

Net Other Operating Income (Loss)(Details 1) (USD $)	3 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013
Deferred Revenue Arrangement [Line Items]
Gain (loss) on foreign currency transactions, net	($2.20)	($2.60)
Exclusivity Payment, Patterson
Deferred Revenue Arrangement [Line Items]
Gain (loss) on foreign currency transactions, net	($1)	$0.80

Derivative_Instruments_and_Hed2

Derivative Instruments and Hedging Strategies (Details) (USD $)	3 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013
Interest rate swap contracts
Interest Rate Risk
Percentage of Debt Hedged by Interest Rate Derivatives	100.00%
Derivative, Lower Fixed Interest Rate Range	1.27%
Derivative, Higher Fixed Interest Rate Range	1.29%
Foreign exchange contracts
Foreign Currency Exposure
Notional Amount	$46.40
Foreign exchange contracts | Gain (loss) on derivative instruments, net | Not Designated as Hedging Instrument
Impact of gains and losses from the fair value changes of the derivative instruments
Gain (Loss) Recognized in Income	$0.40	$0.60

Income_Taxes_Details

Income Taxes (Details) (USD $)	3 Months Ended		12 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Sep. 30, 2014
Income Taxes [Abstract]
Estimated effective tax rate	23.00%	23.50%
Income tax provision	$14	$13.80
Actual effective tax rate			23.00%
United States federal statutory rate	35.00%
Undistributed foreign earnings	$587

Income_per_Share_Details

Income per Share (Details) (USD $)	3 Months Ended
In Millions, except Share data, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013
Income per Share [Abstract]
Net income attributable to Sirona Dental Systems, Inc. common shareholders	$46	$44.20
Weighted average shares outstanding - basic	55,416,418	55,054,040
Dilutive effect of stock-based compensation	873,759	1,075,968
Weighted average shares - diluted	56,290,177	56,130,008
Net income per share
Basic	$0.83	$0.80
Diluted	$0.82	$0.79

Segment_reporting_Details

Segment reporting (Details) (USD $)	3 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013
Revenue
Total	$293	$298.70
Dental CAD/CAM Systems
Revenue
Total	98.2	105.8
Segment Performance Measure
Total	68.4	73.3
Imaging Systems
Revenue
Total	108	105.8
Segment Performance Measure
Total	63.4	61.5
Treatment Centers
Revenue
Total	54	54.4
Segment Performance Measure
Total	21.5	21.2
Instruments
Revenue
Total	32.8	32.7
Segment Performance Measure
Total	13.4	13.5
Total segments
Segment Performance Measure
Total	$166.70	$169.50

Segment_reporting_Details_1

Segment reporting (Details 1) (USD $)	3 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013
Revenue
Consolidated revenue	$293	$298.70
Segement performance measure
Consolidated gross profit	162.9	162.7
Selling, general and administrative expense	-87.8	-88
Research and development expense	-14.8	-15.1
Net other operating income (loss)	2.5	2.5
Gain (loss) on foreign currency transactions	-2.2	-2.6
Gain (loss) on derivative instruments	0.4	0.6
Interest income (expense)	-0.9	-0.8
Other income (expense)	0.7	-0.5
INCOME BEFORE TAXES	60.8	58.8
Total segments
Segement performance measure
Consolidated gross profit	166.7	169.5
Dental CAD/CAM Systems
Revenue
Consolidated revenue	98.2	105.8
Imaging Systems
Revenue
Consolidated revenue	108	105.8
Treatment Centers
Revenue
Consolidated revenue	54	54.4
Instruments
Revenue
Consolidated revenue	32.8	32.7
Differences management reporting vs. US GAAP (including step-up depreciation and certain other corporate items)
Segement performance measure
Consolidated gross profit	($3.80)	($6.80)

Segment_reporting_Details_2

Segment reporting (Details 2) (USD $)	3 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Sep. 30, 2014
Concentration Risk [Line Items]
Accounts Receivable Net Current	155.7		$115.60
Sales Revenue, Goods, Net [Member]
Concentration Risk [Line Items]
Concentration Risk, Percentage	48.00%	47.00%
Sales Revenue, Goods, Net [Member] | Patterson Dental Company, Inc.
Concentration Risk [Line Items]
Concentration Risk, Percentage	35.00%	34.00%
Sales Revenue, Goods, Net [Member] | Henry Schein, Inc.
Concentration Risk [Line Items]
Concentration Risk, Percentage	13.00%	13.00%
Accounts Receivable [Member]
Concentration Risk [Line Items]
Accounts Receivable Net Current	83.6		87.5
Accounts Receivable [Member] | Patterson Dental Company, Inc.
Concentration Risk [Line Items]
Accounts Receivable Net Current	69.8		76.1
Accounts Receivable [Member] | Henry Schein, Inc.
Concentration Risk [Line Items]
Accounts Receivable Net Current	13.8		$11.40

Accumulated_Other_Comprehensiv2

Accumulated Other Comprehensive Income (Loss) (Details) (USD $)	3 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013
Balance at beginning of period	($72.80)	$8.60
Current increase (decrease)	-35.4	16
Income tax (expense) benefit	0.3
Balance at end of period	-107.9	24.6
Other comprehensive income (loss) attributable to noncontrolling interests, net of tax		0.1
Balance at end of period attributable to Sirona Dental Systems, Inc.	-107.9	24.5
Cumulative translation adjustments
Balance at beginning of period	-85.6	2.9
Current increase (decrease)	-34.4	15.8
Income tax (expense) benefit	0
Balance at end of period	-120	18.7
Other comprehensive income (loss) attributable to noncontrolling interests, net of tax		0.1
Balance at end of period attributable to Sirona Dental Systems, Inc.	-120	18.6
Unrecognized elements of pension cost
Balance at beginning of period	13.2	6.4
Current increase (decrease)	-0.9	0.1
Income tax (expense) benefit	0.3
Balance at end of period	12.6	6.5
Other comprehensive income (loss) attributable to noncontrolling interests, net of tax		0
Balance at end of period attributable to Sirona Dental Systems, Inc.	12.6	6.5
Net gain (loss) from hedging instruments
Balance at beginning of period	-0.4	-0.7
Current increase (decrease)	-0.1	0.1
Income tax (expense) benefit	0
Balance at end of period	-0.5	-0.6
Other comprehensive income (loss) attributable to noncontrolling interests, net of tax		0
Balance at end of period attributable to Sirona Dental Systems, Inc.	($0.50)	($0.60)

Inventories_net_Details

Inventories, net (Details) (USD $)	Dec. 31, 2014	Sep. 30, 2014
In Millions, unless otherwise specified
Inventories, net [Abstract]
Finished goods	$90.60	$86.80
Work in progress	12.3	14.3
Raw materials	41.7	39.7
Inventory, gross	144.6	140.8
Inventory reserve	-18.7	-17.4
Inventories, net	$125.90	$123.40

Product_Warranty_Details

Product Warranty (Details) (USD $)	3 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013
Changes in the product warranty accrual
Balance at beginning of the period	$7.60	$9.70
Accruals for warranties issued	4.7	5.6
Warranty settlements made	-4.8	-5.3
Translation adjustment	-0.2	0.2
Balance at end of the period	$7.30	$10.20

Fair_Value_Measurements_Detail

Fair Value Measurements (Details) (Fair Value, Measurements, Recurring, USD $)	Dec. 31, 2014	Sep. 30, 2013
In Millions, unless otherwise specified
Assets
Cash Equivalents (money market funds)	$186.40	$211.20
Derivative Assets	0.2
Liabilities
Derivative Liabilities	-1.3	-1.5
Business Combination-related liabilities	-13.3	-14.2
Total	172	195.5
Quoted Prices in Active Markets for Identical Instruments (Level 1)
Assets
Cash Equivalents (money market funds)	186.4	211.2
Derivative Assets	0
Liabilities
Derivative Liabilities	0	0
Business Combination-related liabilities	0	0
Total	186.4	211.2
Significant Other Observable Inputs (Level 2) | Foreign exchange contracts
Assets
Cash Equivalents (money market funds)	0	0
Derivative Assets	0.2
Liabilities
Derivative Liabilities	-1.3	-1.5
Business Combination-related liabilities	0	0
Total	-1.1	-1.5
Significant Unobservable Inputs (Level 3)
Assets
Cash Equivalents (money market funds)	0	0
Derivative Assets	0
Liabilities
Derivative Liabilities	0	0
Business Combination-related liabilities	-13.3	-14.2
Total	($13.30)	($14.20)

Fair_Value_Measurements_Detail1

Fair Value Measurements (Details 2) (USD $)	3 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2014
Fair Value Measurements [Abstract]
Income statement impact of the acquisition	$0.70
Changes in fair value of contingent consideration	$0.90